Ampyra (Dalfampridine) Patent Expiration, LOE Window & CMS Spending

Ampyra (Dalfampridine) by Merz: Off-Patent Genericized (AB Competition), 5 AB generics, $44.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerz
FDA Application & PathwayN022250 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$44.3M
2024 Medicare Part D Spend$40.3M
2024 Medicaid Spend$4.0M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 32.5% 2-yr change)